As part of our series focussing on medicines available in Australia, we have added a product review on the antiseizure medication (ASM) fenfluramine which is the most recent ASM to have been approved in Australia as add-on treatment for the management of seizures associated with Dravet syndrome (DS). Clinical trial evidence of the efficacy and safety of adjunctive fenfluramine in patients with DS and poorly controlled seizures on their existing ASM regimens is described in this review.
Guiding commentary has been provided by Professor Kate Riney, a Paediatric Neurologist specialised in Epileptology working at the Queensland Children’s Hospital, Brisbane, Australia.
Please login below to download this issue (PDF)